Please login to the form below

Not currently logged in

Abbott and AstraZeneca co-promote Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix.

Under the terms of the agreement, AstraZeneca will gain non-exclusive rights to co-promote Trilipix in the US, excluding Puerto Rico.

Trilipix is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. It is also used in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol.

"Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's total lipid profile," said Jeffrey Stewart, divisional vice president, primary care, Abbott. "With AstraZeneca's established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of Trilipix among physicians whose patients may benefit from this medication."

Jim Helm, vice president, cardiovascular, AstraZeneca US, said: "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, Trilipix is another important therapeutic option we can now offer physicians."

This is the second co-promotion deal between the two pharmaceutical companies. In August 2008 they signed a non-exclusive deal for the co-promotion of AstraZeneca's Crestor in the US market. Specific financial terms of the Trilipix deal were not disclosed.

4th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...